"Anyone know another trading near 1/2 cash with positive news just released? I'd hit your stock!"
SAN DIEGO, July 23, 2015
In addition to advancing Lpathomab into the clinic, Lpath intends to generate in vivo data in select programs, including Altepan™ and other earlier stage preclinical candidates, in order to identify the company's next clinical candidates and indications to pursue. Simultaneously, Lpath will actively explore partnering, licensing and monetization options for its pipeline assets. Lpath's proprietary discovery platform continues to be effective at creating bioactive lipid-targeted monoclonal antibody therapeutics. By reprioritizing its research and development programs, Lpath will continue to advance its discovery science and its pipeline assets.
Lpath's Altepan program continues to make progress and has now shown positive results in preclinical models of pulmonary fibrosis, asthma, inflammatory bowel disease, and other indications. Altepan is a monoclonal antibody targeting members of the cysteinyl leukotriene family, which are important mediators of inflammatory disorders. Altepan is ready to begin IND-enabling development activities to prepare for an IND submission to the FDA as soon as funding is available.
